Long-term follow-up for people who received azer-cel
Part of Cancer clinical trials.
This study checks how people do over a longer period after receiving azer-cel in an Imugene trial. It helps doctors understand long-term safety and health outcomes, even if you are feeling well now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received at least one dose of azer-cel in an Imugene clinical study
- You can sign a study consent form (informed consent)
- You are willing and able to follow the study’s visit schedule and instructions
- There are no special exclusion rules listed for this follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
This trial tests an investigational cell therapy called Azer-cel in people with certain autoimmune diseases that affect the nerves or muscles. It aims to see if the treatment is safe and can help reduce symptoms by targeting the immune system.
This study tracks the long-term safety and effects of azer-cel, a cell-based cancer treatment, in people who previously received it in an earlier trial. Researchers want to understand how the treatment works over time and ensure your ongoing health.
This trial is for people who have already received a cell or gene therapy in another AstraZeneca study. It simply checks in on your health over time after that treatment.
This is a long-term follow-up study for people who have already received gene-modified T-cell therapy. It observes your health over time to see how well the treatment worked and any long-term effects.
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
Hear when a new Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.